Global Search | Novartis United States of America

Sort by

Relevance

Newest first

Oldest first

Hide Filters

Showing 708 results

Media Release / Mar 27, 2019

Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease
Media Release / Mar 16, 2019

Novartis late-breaking data further support initiation of Entresto in hospital and as a first-choice systolic heart failure therapy in stabilized patients

- Outcomes from PIONEER-HF 4-week open-label extension reinforce initial 8-week findings, showing Entresto® (sacubitril/valsartan) continued to deliver reductions in NT-proBNP, an established…
Media Release / Mar 16, 2019

Novartis late-breaking data further support initiation of Entresto in hospital and as a first-choice systolic heart failure therapy in stabilized patients
Media Release / Jan 28, 2019

Novartis data show psoriasis patients treated with Cosentyx® reported improvements in quality of life measures as early as Week 4

- Psoriasis patients receiving Cosentyx (secukinumab) reported improvements beyond the skin in mobility, self-care, and usual activities versus patients receiving placebo(1)- Skin lesions are only…
Media Release / Jan 28, 2019

Novartis data show psoriasis patients treated with Cosentyx® reported improvements in quality of life measures as early as Week 4
Media Release / Jan 08, 2019

Novartis investigational therapy crizanlizumab (SEG101) receives FDA Breakthrough Therapy designation for the prevention of vaso-occlusive crises in sickle cell disease

- Crizanlizumab is a monthly infusion under development to prevent pain crises (also called vaso-occlusive crises, or VOCs) in patients with sickle cell disease- Sickle cell VOCs, which are triggered…
Media Release / Jan 08, 2019

Novartis investigational therapy crizanlizumab (SEG101) receives FDA Breakthrough Therapy designation for the prevention of vaso-occlusive crises in sickle cell disease
Media Release / Dec 08, 2018

Novartis data demonstrates consistent efficacy and tolerability of Kisqali® combination therapy in HR+/HER2- advanced breast cancer in patients with difficult-to-treat visceral disease

-Subgroup analyses of three pivotal Phase III MONALEESA trials showed Kisqali plus endocrine therapy extended PFS in all patients with and without visceral involvement compared to endocrine therapy…
Media Release / Dec 08, 2018

Novartis data demonstrates consistent efficacy and tolerability of Kisqali® combination therapy in HR+/HER2- advanced breast cancer in patients with difficult-to-treat visceral disease
Media Release / Dec 06, 2018

Novartis investigational BYL719 (alpelisib) plus fulvestrant consistently improved PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer in new SOLAR-1 analyses

- BYL719 plus fulvestrant meaningfully prolonged PFS vs fulvestrant alone in patients with PIK3CA mutated HR+/HER2- advanced breast cancer after progression on an aromatase inhibitor or after…

‹ Previous page
1
…
26
27
28
29
30
31
32
…
71
› Next page